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Conventional breast cancer extirpation involves resection of parts of or the whole gland, resulting in asymmetry and disfiguration.
Given the unsatisfactory aesthetic outcomes, patients often desire postmastectomy reconstructive procedures. Autologous fat
grafting has been proposed for reconstructive purposes for decades to restore form and anatomy after mastectomy. Fat has the
inherent advantage of being autologous tissue and the most natural-appearing filler, but given its inconsistent engraftment and
retention rates, it lacks reliability. Implementation of autologous fat grafts with cellular adjuncts, such as multipotent adipose-
derived stem cells (ADSCs), has shown promising results. However, it is pertinent and critical to question whether these cells
could promote any residual tumor cells to proliferate, differentiate, or metastasize or even induce de novo carcinogenesis. Thus
far, preclinical and clinical study findings are discordant. A trend towards potential promotion of both breast cancer growth and
invasion by ADSCs found in basic science studies was indeed not confirmed in clinical trials. Whether experimental findings
eventually correlate with or will be predictive of clinical outcomes remains unclear. Herein, we aimed to concisely review current
experimental findings on the interaction of mesenchymal stem cells and breast cancer, mainly focusing on ADSCs as a promising
tool for regenerative medicine, and discuss the implications in clinical translation.
1. Introduction
Breast cancer is the most-frequently diagnosed cancer and a
leading cause of cancer-related death in women worldwide
[1–3]. Great effort has been put into pursuing the understand-
ing of breast cancer development, progression, and invasion,
as well as implementation of appropriate therapies. Depend-
ing on breast cancer stage, therapy may include chemother-
apy, irradiation, and, most frequently, surgical treatment
ranging from local excision and lumpectomies to modified
and radical mastectomies. Oncological surgery is disfiguring
and the original anatomical contours of the breast often
require reconstitution. Besides the use of synthetic prosthet-
ics or flap surgery, a more recent alternative for restoring
the breast shape and camouflaging scars is transplantation
of autologous lipoaspirates, referred to as “lipofilling” or
“fat grafting.” Ideally, autologous fat transplantation has the
advantage of providing a more natural appearance after
reconstruction, in addition to being readily available tissue
coupled with low donor-site morbidity from liposuction as
compared to flap surgery [4]. However, long-term outcomes
are unpredictable in terms of engraftment of transplanted fat
aliquots, as there is a variable loss of volume, which often
dictates unsatisfactory final outcomes and the necessity for
repetitive lipofilling sessions [5–7]. The reason has mainly
been attributed to poor vascularization of fat grafts with
consequent fat necrosis and/or apoptosis [5]. To overcome
this drawback, supplementation with adipose-derived stem
cells (ADSCs) isolated from white adipose tissue (WAT) has
been proposed, which is believed to improve fat engraftment
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[5, 7–9] and have additional positive effects on scars and
damaged skin after irradiation therapy [10, 11].These cells are
incorporated in the autologous fat graft but can be isolated to
further enhance the regenerative potential of smaller volume
injections.
ADSCs share similarities with mesenchymal stromal
cells (MSCs) isolated from bone marrow (BM-MSCs) [12].
Through cytokine and growth factor release, ADSCs have
shown several beneficial effects in inflammatory and autoim-
mune diseases and ischemic conditions [13–15]. Moreover,
inherent advantages over MSCs isolated from other tissues,
such as higher yields and lower harvest site morbidity [16], as
well as their natural relation to WAT itself, make ADSCs an
ideal tool for soft tissue reconstruction. Early reports show
beneficial effects of ADSCs on autologous fat grafting with
improved retention rates when coinjected [4, 9, 17–19].
MSCs are able to home to sites of tissue injury and
inflammation [20], as well as the cancer microenvironment
(CME) [21, 22]. In this regard, some authors proposed the
use of MSCs either as a vector for anticancer therapy or as
an adjunct treatment for increasing cancer cell susceptibility
to chemotherapies [23, 24].
However, both BM-MSCs and ADSCs are also suspected
to promote tumor development and progression, as well as
recurrence in different cancer types [25–27].MSCs in general
have controversially been reported to support [26, 28–31]
or to suppress [32–34] cancer cells. Thus, considering the
fact that the risk of breast cancer recurrence is up to 13%
after adjuvant therapy [35], investigating the effects of ADSCs
on breast cancer prior to performing ADSC-enhanced fat
grafting for reconstructive purposes after oncological surgery
on a routine basis is of the utmost importance.
Several mechanisms have been proposed through which
ADSCs, and more in general MSCs, interact with cancer
cells and influence their microenvironment. These include
paracrine signaling and cell-to-cell signaling, as well as
differentiation into cancer-associated myofibroblasts (CAFs)
or incorporation into newly formed vessels, leading to mor-
phological and functional alterations of both cancer cells
and MSCs in a bidirectional manner and the cancer niche
itself [36–38]. Furthermore, several reports on the interaction
between ADSCs and breast cancer cells (BCCs) have been
published [30, 38–43].
The use of ADSCs for reconstructive purposes after breast
cancer surgery has gained attention in recent years. The
effects of ADSCs, which might improve fat retention after
soft tissue reconstruction, potentially could be beneficial for
the survival and promotion of residual cancer cells, a sort
of “double-edged sword.” In this review, we will focus on
the influence of ADSCs on BCCs and concisely summarize
different putativemechanisms potentially involved in promo-
tion and spread of breast cancer and discuss the difference to
actual clinical findings.
2. Adipose-Derived Stem Cells
Just over a decade ago, Zuk et al. reported a multipotent,
undifferentiated, self-renewing progenitor cell population
isolated from WAT that is morphologically and phenotyp-
ically similar to BM-MSCs [12]. ADSCs were found to be
able to differentiate into a variety of mesenchymal lineages
including adipogenic, osteogenic, chondrogenic, and hepa-
tocytic differentiation [12]. Through paracrine secretion of
a broad selection of cytokines, chemokines, and growth
factors, ADSCs have been shown to have antiapoptotic,
proangiogenic, anti-inflammatory, immunomodulatory, and
antiscarring effects. This potential makes them promising
candidates for cellular therapy in regenerative medicine [9,
15, 44, 45]. Unlike bone marrow, fat is abundantly available
and easily accessible through liposuction and can yield
significantly higher amounts of cells, which makes adipose-
derived cells appealing for regenerative medicine [14].
2.1. Sources and Subpopulations of ADSCs. The most com-
mon source for ADSCs is abdominal fat [23, 46, 47], as
well as breast tissue, either after reduction mammoplasty
[42, 48, 49] or after breast cancer surgery [50, 51].The surgical
technique and the back-table processing after harvesting are
not discussed in detail in the reviewed papers.Thus, any com-
parisons between studies that will facilitate standardization of
such parameters remain a challenge. It has been shown that
the anatomical location of harvest can influence proliferation
and function [52], differentiation ability [53], and apoptotic
susceptibility [54] of ADSCs. For example, ADSCs derived
from superficial abdominal fat depots [54] are more resistant
to apoptosis, which might be relevant to ADSC survival in
the highly active tumor microenvironment. Indeed, ADSCs
from different anatomical regions (e.g., inguinal, omental,
and pericardial) have been found to express different surface
marker patterns [55] and the cell yields of ADSCs also vary
by anatomical region of isolation [56].
Breast ADSCs seem to express similar surface marker
phenotypes as abdominal ADSCs (positive for CD29, CD73,
CD90, and CD105 and negative for CD14, CD31, CD34,
and CD45) according to a recent report by Hanson et al.
[57], although CD34 expression was found to differ between
breast ADSCs isolated from cancer-affected mammary fat
and normal breast fat tissue [58]. Regardless of the passage,
ADSCs derived from normal breasts were CD34+, in contrast
to CD34-negativity in cancer afflicted breast tissue-derived
ADSCs. This is in contrast to a recent report by Yang
et al., which found only minimal expression of CD34 in
normal breast-derived ADSCs [48]. Nevertheless, ADSCs
from abdominal and normal breast fat share similar genetic
profiles [59]. Moreover, reports of ADSCs isolated from
primary breast cancer tissue have been published [50, 60–62].
After homogenization of whole fat or lipoaspirates,
a pooled cell pellet, the stromal vascular fraction (SVF),
remains. The SVF contains a heterogeneous population
of cells that includes at least four subpopulations with
distinct surface marker phenotypes, in addition to
erythrocytes and lymphocytes, namely, endothelial
progenitor cells (EPCs; CD45−CD31+CD34+), mature
endothelial cells (ECs; CD45−CD31+CD34−), pericytes
(CD45−CD31−CD34−CD146+), and supra-adventitial ADSCs
(CD45−CD31−CD34+) [63, 64]. Adipose-derived pericytes
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Table 1: Most common human BCC lines used for investigation of ADSC/breast cancer interaction [68, 69, 191].
BCC line Classification ER PR Her2 In culture Notes References
MCF-7 Luminal A + ± − Mass Endocrine responsiveIsolated fromMPE [36, 42, 46, 47, 50, 58, 61, 70–73, 98, 109]
MDA-MB-231 Basal B, claudin-low − − − Stellate Isolated fromMPE [22, 30, 36, 38, 42, 49, 71–74, 89, 109]
T47D Luminal A + ± − Mass Endocrine responsiveIsolated fromMPE [70, 73, 93]
BT-474 Luminal B + + + Mass
Endocrine and Trastuzumab
responsive
Isolated from primary tumor
[70, 71]
HCC1937 Basal A − − − n/a Isolated from primary tumor [41, 43]
MDA-MB-436 Basal B − − − Stellate Isolated fromMPE [41, 43]
ZR 75.1 Luminal B + ± + Grape-like
Endocrine and Trastuzumab
responsive. Isolated from
ascites
[39, 41]
SKBR3 Luminal, Her2 − − + Grape-like Trastuzumab responsiveIsolated fromMPE [23]
T4-2 (HMT-3522) Basal B − − − Mass Isolated from primary tumor [74]
BC: breast cancer; BCC: breast cancer cell; ER: estrogen receptor; Her2: human epidermal growth factor receptor 2; MPE: metastatic pleural effusion; n.s.: not
specified; PR: progesterone receptor.
are rare (∼1% of SVF) and are thought to be a progeny for the
less primitive ADSCs, which express mesenchymal surface
markers such as CD73, CD90, and CD105, but also CD34
[65]. However, the International Society for Cell Therapy
(ISCT) definition for plastic adherent MSCs clearly includes
the absence of CD34 [66]. Nevertheless, both pericytes and
ADSCs have excellent adipogenic differentiation potential,
which makes them both ideal cells for reconstructive
purposes [63, 64]. CD34+ cell prevalence in fat grafts
correlates with extent of graft retention and shows individual
variability among patients [9]. In a joint statement paper
from the International Federation for Adipose Therapeutics
and Science (IFATS) and the ISCT, ADSCs were defined as a
CD34+ subpopulation of the SVF [67].
Among the different studies investigating ADSCs and
BCCs, there is a consensus that ADSCs express mesenchymal
surface markers such as CD29, CD44, CD73, CD90, and
CD105 and lack hematopoietic and endothelial markers (e.g.,
CD31, CD45). However, reports of CD34 expression are
conflicting, with different authors naming “ADSC” cell pop-
ulations either with or without CD34 expression. One should
keep this in mind when comparing experimental results,
since different expressions of CD34 could mean different cell
subpopulations, in addition to the potential effects of culture
on surfacemarker phenotype switch or loss [51]. Different cell
subpopulations of the SVF are likely to share similarities and
overlap in some surface marker expression but might have
slightly different differentiation potential and/or functional
characteristics [44]. The translational relevance of CD34
expression currently remains unclear.
In this review, ADSCs will be generally termed as those
adipose-derived cells which are plastic adherent and can be
expanded in culture after isolation of the SVF.This comprises
cells that present a heterogeneous expression of CD34 but
express unquestionable mesenchymal markers (e.g., CD29,
CD44, CD73, CD90, and CD105) and lack hematopoietic and
other endothelial markers (e.g., CD31, CD45).
3. Breast Cancer Cell Lines
Table 1 gives an overview of the BCC lines most commonly
used for experimental studies on ADSCs and breast cancer
interaction [68, 69]. Mainly, most of the experiments make
use of human cell lines in humanized murine (xenotrans-
plant) models in vivo. MCF-7 is the most common cell line
used, especially to assess drivingmechanisms of breast cancer
progression from a relatively low malignancy to an invasive
and metastatic phenotype [36, 42, 46, 47, 50, 70, 71]. The
MDA-MB-231 line, on the other hand, is mostly used to
investigate metastatic spread and basic biology of aggressive
breast cancers [22, 30, 42, 72–74]. The different cell lines
have distinct characteristics in culture and in vivo and may
be used for specific research aims, so MCF-7 and BT-474
cells are ideal for investigation of hormone-receptor roles and
their associated therapeutic approaches; ZR75.1 and SKBR3
cells, bothHER-2 positive, might be used for testing therapies
similar to trastuzumab; MDA-MB-231 and MDA-MB-436
are used for research on “triple-negative,” basal-like breast
cancers [69].
Many of these cell lines were isolated many decades ago
andwere immortalized, with changes to both gene expression
and phenotype over time as a potential consequence. A
number of commonly used cell lines such as MCF-7 were
isolated from metastatic pleural effusions (MPEs) and might
not depict the most common tumor biology but an advanced
one, due to originating from a metastatic cancer.
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4. Interactions between Adipose-Derived Stem
Cells and Breast Cancer Cells
4.1. ADSC Homing and Migration. There is evidence that
MSCs home to injured tissue, sites of inflammation, and
tumor niches [20, 21, 75]. This has been shown in vivo when
administered intravenously and also for endogenous MSCs
[76]. Tumor irradiation also promotes MSC recruitment
into the irradiated area, probably due to induced tissue
inflammation [77] or the necessity for tissue repair. Due to
their inherent ability to home to cancer tissue as well as
hinting to sensitizing cancer cells for chemotherapy, MSCs
have also been proposed as vehicles for targeted anticancer
drugs or gene therapy [49, 78, 79].
There are a multitude of surface signaling molecules,
cytokines, and chemokines that are able to induce and control
MSC recruitment and migration from their physiological
niches and their homing into the injured tissues and can-
cer. Granulocyte colony stimulating factor and granulocyte-
macrophage colony stimulating factor are two of the most
well-known factors widely used for stem cell mobilization in
the clinical setting [80, 81]. Stromal-derived factor 1 (CXCL-
12) and its receptor CXCR-4 are also key players in cellular
homing [82, 83] and have been shown to be involved in MSC
migration, in addition to having an important role also in
(tumor) angiogenesis [84]. Other molecules, for example,
vascular cell adhesion molecule 1, MCP-1, and MMPs, are
also involved in the complex andmultifactorial MSC homing
process [85–87].
ADSCs as a component of WAT are physiologically
located in the breast and potentially near any occurring breast
cancer. Moreover, additional ADSCs could be inoculated
through reconstructive cell-assisted lipografting close to the
cancer bed. This is different than BM-MSCs, which must
be recruited through mobilization from the bone marrow
into circulation and home to cancer. An interesting study by
Kidd et al. suggests that mobilization from both fat and bone
marrow may be induced by breast cancer, with the two cell
types playing distinct roles in the CME [76]. In vitro, ADSCs
have been found to migrate towards conditioned medium
(CM) of both MDA-MB 231 and 4T1 breast cancer cells [88].
Karnoub et al. observed homing of intravenous-applied
MSCs to the tumor niche, with no evidence of accumulation
in filtering organs [26]. This agrees with another work
showing viable GFP+ ADSCs in breast cancer tumors after
two weeks in a perivascular location [89] after homing. Other
reports indicate substantial engraftment of human MSCs in
the liver in addition to being present in tumor tissue for
weeks [90]. Regardless of local or intravenous delivery, they
promoted both tumor growth and invasiveness [30]. Direct
coinjection of ADSCs and BCCs increased growth to a higher
extent, suggesting a partial entrapment of injected cells in
filtering organs (e.g., lungs, spleen, and liver). ADSCs within
the tumor survived for at least 20 days and were found
to differentiate into ECs and incorporate into new cancer-
associated vasculature. In Karnoub’s study, metastases were
increased under the influence of MSCs for several BCC lines,
including high malignant MDA-MB-231 and low malignant
MCF-7 cells. This effect was abolished when MSCs were
injected in the mammary pad contralateral to developing
breast cancer, unlike results of another report, where, inter-
estingly enough, cells injected subcutaneously were able to
home to the tumor site on the contralateral mammary pad
through blood circulation [89], underscoring the ability of
MSCs to home to sites of tissue damage following different
paths.
4.2. Cancer Promotion and Suppression. Studies investigating
the impact of ADSCs, and more in general MSCs, on cancer
growth dynamics and patterns, as well as progression to
metastatic disease, revealed somewhat contradictory results,
showing both promoting and suppressing effects. Tables 2 and
3 summarize themost important experimental in vitro and in
vivo studies, respectively.
In their 2007 study, Karnoub et al. reported that BM-
MSCs promote the disposition of BCCs to migrate when
cocultured with low malignancy cell lines such as MCF-7
[26]. A number of preclinical studies followed, suggesting
that BM-MSCs can exert a promoting influence on the
growth and spread of breast cancer [29, 31, 91, 92]. In 2009,
the first reports showing similar cancer-promoting effects
with the use of ADSCs were published, depicting that the
issue might extend to MSCs coming from different sources
as well [38, 73]. In a similar fashion, Kucerova et al. found
that BM-MSCs and ADSCs promoted proliferative effects in
a variety of BCC lines [93], but not on SKBR3 [23]. This
was in line with reports from a Chinese group, which found
decreased tumor proliferation with high numbers of MSCs
[34, 94]. Sun et al. also showed that human BM-MSCs and
ADSCs homed to tumors and were able to inhibit growth of
high malignancyMDA-MB-231 cells and decrease metastatic
spread of a normally migratory cell line in vivo [49]. These
findings were confirmed in later studies by the same group
with both umbilical cord-derived MSCs and ADSCs injected
simultaneously with or three weeks after inoculation of BCCs
[95]. This might be a very important finding, as the timing
might more appropriately reflect the clinical scenario of stem
cell-enhanced autologous fat grafting.
Rowan and colleagues discovered that ADSCs did not
increase proliferation in triple-negative BCCs but did slightly
in hormone-receptor positive cells such as MCF-7 and BT-
474. On the other hand, not only the in vitro migration
potential of triple-negative MDA-MB-231 was enhanced by
ADSCs, but also their CM was enough to achieve similar
results, suggesting a paracrine mechanism [71]. These results
are similar to those observed with the bone marrow-derived
counterpart in the earlier report by Karnoub et al. [26].
Of WAT-derived cells, CD34+ cells seem to be at least
partly responsible for tumor-promoting ability, as they
increased tumor sizes significantly when coinjected with
BCCs. In addition, CD34+ cells seem to be more efficient
in a metastatic shift of triple-negative MDA-MB-436 and
HCC1937 cells in a murine xenograft model [43]. In a study
published later by the same group, two distinct CD34+ pop-
ulations were found to act in concert when promoting breast
cancer growth [41]. EPCs promoted neovascularization to a
higher extent and were more prone to migration into lymph
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Table 2: Relevant in vitro studies investigating the effects of ADSCs on breast cancer.
Reference Year ADSC origin ADSC surface marker BCC line Effects on BCC
Trivanovic´ et al.
[58] 2014
Human breast
(normal versus
cancer-affected) and
abdominal
CD44+CD73+CD90+CD105+
CD11a−CD33−CD45−CD235a−
HLA-DR−CD34±
MCF-7
Proliferation↑ (direct coculture)
Proliferation↓
(indirect coculture)
Different ADSCs had similar
effects
Kucerova et al.
[23] 2013 Human lipoaspirates
CD29+CD44+CD90+CD105+
CD14−CD34−CD45− SKBR3
Proliferation↓, migration↑
EMT markers↑
BCC chemosensitivity↑
Lin et al.
[46] 2013 Human lipoaspirates
CD29+CD44+CD105+
CD31−CD34−HLA-DR− MCF-7
Proliferation and migration↑
Cell-to-cell contact needed
Wnt pathway↑
Strong et al.
[72] 2013
Human abdominal
versus nonabdominal n.s.
MCF-7,
MDA-MB-231
Proliferation↑
Leptin/estrogen-dependent
Increased effect of abdominal
ADSCs from obese (versus lean
and nonabdominal ADSCs)
Zhang et al.
[50] 2013
Human breast
(cancer-affected)
CD13+CD29+CD44+CD71+
CD105+HLA-I+
CD4−CD10−CD14−CD34−
CD38−HLA-DR−
MCF-7 Proliferation↑Migration↑
Zhao et al.
[47] 2013
Human lipoaspirates
(abdominal)
CD29+CD44+CD105+
CD34−CD45− MCF-7
Migration↑
Angiogenesis↓
MMPs↑
Devarajan et al.
[70] 2012
Human whole fat n.s.
4T1 (murine)
BT-474, MCF-7,
T47D
Proliferation↑, EMT markers↑
PDGF-dependent (paracrine)
Jotzu et al.
[109] 2011
Human whole fat CD29+CD44+CD90+CD105+
CD14−CD34−CD45−
MCF-7,
MDA-MB-231
Migration and invasion↑
ADSCs differentiate to CAFs
Kucerova et al.
[93] 2011 Human lipoaspirates
CD44+CD73+CD90+CD105+
CD14−CD34−CD45−
MCF-7, T47D,
MDA-MB-361
BCC proliferation↑
(dose-dependent)
Paracrine mechanism
Razmkhah et al.
[61] 2011
Human breast
(cancer-affected)
CD44+CD105+CD166+
CD14−CD34−CD45− MCF-7
Anti-inflammatory cytokines↑
T regs↑
Yan et al.
[98] 2012
Human breast
(normal versus
cancer-affected)
CD29+CD73+CD90+CD105+
CD166+
CD31−CD144−CD14−CD45−
HLA-DR−
MCF-7
Proliferation↑
(BC ADSCs > normal breast
ADSCs)
EGF/EGFR/Akt-dependent
Pinilla et al.
[38] 2009 Human abdominal n.s. MDA-MB-231
Proliferation↑, RANTES↑
Migration↑, MMPs↑
Welte et al.
[73] 2012
Human lipoaspirates
(abdominal)
CD44+CD90+CD105+
CD11b−CD14−CD34−CD45−
HLA-DR−
MCF-7,
MDA-MB-231,
T47D
ADSC migration towards BCCs
Migration and invasiveness↑
IL-8↑
ADSC: adipose-derived stem cell; BC: breast cancer; BCC: breast cancer cell; CAF: cancer-associated (myo) fibroblast; EMT: epithelial-to-mesenchymal
transition; ER: estrogen receptor; Her2: human epidermal growth factor receptor 2; MMPs: matrix metalloproteinases; MPE: metastatic pleural effusion; n.s.:
not specified; PR: progesterone receptor; T reg: regulatory T lymphocyte.
nodes andmetastasis formation, whereas ADSCs locally pro-
moted tumors more than EPCs. Strikingly enough, CD34−
cells promoted growth to a lesser extent, and metastases
were similar to controls without WAT cells. Ironically, the
CD34+ subpopulation is the one which shows high benefits
for retention of fat grafts and therefore would be an appealing
tool for reconstructive efforts [9].
Noteworthily, two published papers by Ke et al. and
Zimmerlin et al. included in vivo models in which they
seeded cancer cells in numbers as low as ten and 100 cells,
respectively [5, 96]. The first group showed that ten murine
4T1 breast cancer cells (low malignancy) were able to grow
into a tumor and metastasize upon coinjection with murine
BM-MSCs, whereas the same BCCs alone failed to do so [96].
The authors suggested increased angiogenesis, as depicted
by enhanced vascularity next to GFP+ BM-MSCs as one of
the mechanisms. Interestingly enough, and in contrast to
other studies, MSCs were not present in the tumor at later
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Table 3: Relevant in vivo studies investigating the effects of ADSCs on breast cancer.
Reference Year Model ADSC origin ADSC surface markers BCC line RatioBCC/ADSC Effects on BCC/BC
Eterno et al.
[60] 2014 Mouse
Human
lipoaspirates and
breast whole fat
(normal versus
cancer-affected)
CD44+CD90+CD117+
CD133+
CD34lowCD45−
MCF-7,
MDA-MB-231,
primary BCCs
2 : 1
No changes in MCF-7
MDA-MB-231 growth and
migration↑
EMT↑
Paracrine, IL-8↑, IL-6↓
Rowan et al.
[71] 2014 Mouse
Human
lipoaspirates
(abdominal)
CD29+CD34+CD73+
CD90+CD105+
CD44lowCD45low
BT-474, MCF-7,
MDA-MB-231 1 : 1
Tumor growth↔
Migration and metastasis↑
EMT induction
Orecchioni
et al. [41] 2013 Mouse
Human
lipoaspirates
CD31+CD34+CCRL2+
CD13−CD45− (EPC)
and CD13+CD34+
CD140b+
CD31−CD45− (ADSC)
HCC1937,
MDA-MB-436,
ZR75-1
5 : 1
Tumor growth↑
Metastatic spread↑
EMT↑
Effect of ADSCs > EPCs
Chandler
et al. [36] 2012 Mouse
Human
lipoaspirates
CD13+CD29+CD44+
CD73+CD90+CD105+
CD166+
CD14−CD31−CD45−
MCF-7,
MDA-MB-231 1 : 1
Tumor growth↑
Angiogenesis↑
Bidirectional signaling
ADSCs differentiate to CAFs
Zhang et al.
[22] 2012 Mouse
Murine
(endogenous)
CD34+
CD31−CD45−
E0771,
MDA-MB-231 n.s.
Circulating ADSCs↑ in cancer
ADSCs incorporate into tumor
vasculature (as pericytes)
Zhao et al.
[74] 2012 Mouse
Human breast
(normal)
CD29+CD73+CD90+
CD105+
CD14−CD31−CD45−
HMT-3522 S3
(preinvasive),
HMT-3522 T4-2
(invasive),
MDA-MB-231
1 : 1, 3 : 2
Tumor growth↑
Tumor invasiveness↑
Angiogenesis↔
No effect on preinvasive BCCs
Dirat et al.
[39] 2011 Mouse
Murine 3T3
adipocytes —
4T1, 67NR,
(murine)
ZR 75.1,
SUM159PT
n.s. Metastatic spread↑IL-6-dependent
Martin-
Padura
et al. [43]
2012 Mouse Murine whole fat CD34
+
CD45−
HCC1937,
MDA-MB-436 5 : 1
Tumor growth↑
Metastatic spread↑
Angiogenesis↑
Zimmerlin
et al. [5] 2011 Mouse
Human abdominal
whole fat
CD34+CD44+CD73+
CD90+CD105+CD146+
CD45−CD31−
Human MPE n.s. Tumor growth↑ (active cells,but not resting cells)
Muehlberg
et al. [30] 2009 Mouse Murine whole fat
CD44+CD90+CD105+
CD11b−CD14−CD34−
CD45−HLA-DR−
4T1 (murine),
MDA-MB-231 1 : 10
Tumor growth↑
Metastatic spread↑
Paracrine through SDF-1
ADSCs home to tumor and
differentiate to ECs
Sun et al.
[49] 2009 Mouse
Human breast
whole fat n.s. MDA-MB-231 2 : 1
Tumor growth↓
Metastatic spread↓
No early carcinogenesis
improvement
Walter et al.
[42] 2009 Mouse
Human breast
whole fat and
abdominal
lipoaspirates
n.s. MCF-7,MDA-MB-231 1 : 1
Tumor migration and
invasiveness↑
IL-6-dependent
Zhang et al.
[89] 2009 Mouse
Murine whole fat
(obese mice)
CD34+
CD31−CD45− (ADSC)
and CD31+CD34+
CD45− (EPC)
4T1, EF43.fgf4
(murine),
MDA-MB-231
n.s.
Tumor growth↑
ADSCs home to tumor
(perivascular space)
ADSC: adipose-derived stem cell; BC: breast cancer; BCC: breast cancer cell; EC: endothelial cell; EMT: epithelial-to-mesenchymal transition; EPC: endothelial
progenitor cell; ER: estrogen receptor; Her2: human epidermal growth factor receptor 2; MMPs: matrix metalloproteinases; MPE: metastatic pleural effusion;
n.s.: not specified; PR: progesterone receptor; T reg: regulatory T lymphocyte.
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time points beyond 11 days [96]. Zimmerlin et al. isolated
cells in different dormancy states: persistent, dormant cells
after surgical therapy and active cells representing the active
disease as a primary or recurrent tumor.The authors isolated
mainly three cancer cell types, namely, small resting and
large active cancer cells, both CD90+ and a third CD90−
population. Small resting cells were rare and represented only
a small portion of the isolated cells. However, these cells may
potentially lead to recurrence [5]. Combined with ADSCs,
100 small resting cells were not affected. The same aliquot of
large cells was not capable of developing a cancer nodule but
developed to a significant size when coinjected with ADSCs.
These findings could be explained by the autonomy of slow-
growing dormant cells, whereas active cells require a high
amount of growth factors and good vascularity. This is in
line with other findings in which breast ADSCs were able to
promote the progression and invasion of the invasive cancer
cell line T4-2, but not its preinvasive variant HMT-3522 S3
[74]. These results suggest that fat grafts supplemented with
ADSCs for reconstruction could be used in patients after
complete and terminated cancer-therapy and documented
healing, since they may affect active but not resting cancer
cells [5].
4.3. MSCs and the Cancer Microenvironment. Besides being
a highly proliferative and dynamic mammary gland tissue,
breast tissue contains a stroma with a heterogeneous cell
population including adipocytes, myofibroblasts, MSCs, and
ECs, as well as macrophages and other immune system cells
[97]. Similarly, this stroma is actively involved in creating the
CME, which is composed of highly proliferative malignant
cancer cells and several nonmalignant elements including
cancer-associated vessels, the extracellular matrix (ECM),
CAFs [36, 76], stromal cells such as MSCs [98], and immune
cells like macrophages and lymphocytes [99]. Emulating
a chronic wound and secreting chemoattractant factors,
tumors “trick” and attract MSCs from the bone marrow and
possibly other locations such as local and peripheral fat [100].
The interaction between the stroma resident cells such as
ADSCs and cancer-associated fibroblasts and primary cancer
cells is sophisticated and happens in a bidirectional fashion,
with the different cells influencing each other on different
levels. MSCs that have homed to a tumor can have different
fates: they may survive and exist as MSCs or differentiate into
another cell type, such as ECs, pericytes, or CAFs [101–103].
MSCs andCAFs share similarities in regard to phenotype and
surface markers, but CAFs additionally express fibroblast-
specific protein and fibroblast activation protein, as well as 𝛼-
SMA, and have been shown to produce higher levels of IL-4,
IL-10, TGF-𝛽1, andVEGF [104].The basal-like CD44+CD90+
small cells at the stroma/tumor interface cross talk with
surrounding CAFs, which provides an ideal niche for the
growing tumor mass. Those cells later migrate to the inside
of the tumor bulk and become highly proliferative CD44+90−
cells. Noteworthily, theCD44+90+ cells have been regarded as
tumor cell progenitors and might serve as cancer stem cells
(CSCs) [40].
BM-MSCs and ADSCs have been shown to differentiate
into CAFs in vivo and in vitro [103, 105–109]. Kidd et al. found
that CAFs originate mainly from endogenous bone marrow
precursor cells, whereas progenitor cells from local adipose
tissue are the origin of pericytes and ECs involved in the
growing cancer vascular network and constitute the majority
of the recruited cells [76]. Also, to their advantage, CAFs can
be activated by BCCs, leading to increased tumor growth
[84].
ADSCs in culture with CM from MDA-MB-231 and
MCF-7 tumors partly differentiated into myofibroblasts and
promoted cancer invasion ability in vitro through a TGF-
𝛽1/Smad dependent pathway [37]. This depicts bidirectional
signaling, reciprocal influence, and consequent phenotype
modifications between ADSCs and BCCs [36]. Breast car-
cinomas often involve a desmoplastic reaction similar to
the one found during the healing process in wounds [74].
The EGF/EGFR/Akt-dependent pathway was shown to be
involved and the promoting effect reverted after EGF-
blockade [98].
Accumulating evidence suggests that chronic inflamma-
tion, as found in tumors, is involved in the progression and
recurrence of breast cancer [110]. Immune system cells can
attract many other host cells, including macrophages and
MSCs [111, 112]. Macrophages secrete relevant amounts of
MMPs, which increase the invasion ability of cancer [110] and
are able to suppress T-cell antitumor effects through a HIF-
𝛼 dependent pathway [113]. MSCs show inhibitory effects on
local immune reaction against breast cancer, with increased
T reg (CD4+FoxP3+) levels in tumors and diminished natural
killer cells [90]. Moreover, MSCs are activated to secrete anti-
inflammatory cytokines when exposed to proinflammatory
cytokines in the tumor milieu, which enables tumor immune
evasion [104, 114]. ADSCs isolated from breast cancers also
secrete high levels of immunosuppressive cytokines such as
IL-4, IL-10, and TGF-𝛽1 [61].
4.4. Cytokines, Chemokines, and Growth Factors: The Influ-
ence of Paracrine Signaling versus Cell-to-Cell Contact.
To shed light on further mechanisms besides endocrine-
and hormone-dependent pathways, several studies have
addressed the question of whether cell-to-cell contact pro-
motes breast cancer progression under ADSC influence [23,
46, 58, 88, 104, 115]. ADSCs are known to secrete growth
factors, cytokines, and chemokines [15, 93]. Indeed, several
factors are increasingly present in the CME, including HGF,
IL-6, IL-8, SDF-1, TNF-𝛼, TGF-𝛽1, and VEGF [39, 104].
However, their specific role in breast cancer is still poorly
understood, even though some of the mediators such as IL-
6 and TGF-𝛽1 seem to be clearly involved in progression
of breast malignancies into a more malignant phenotype
[39, 106, 116].
In their 2011 published work, Kucerova et al. found that
ADSC-CM increased BCC proliferation in a dose-dependent
manner, suggesting a cell-to-cell contact-independent mech-
anism. The CM contained high levels of IL-6, IL-8, MCP-
1, and VEGF [93]. Strikingly, coculture of BCCs with CM
was more potent in promoting proliferation than direct
coculture of the cells. In a recent work, the same authors
further investigated the paracrine effects of ADSCs on
the triple-negative cell line SKBR-3 and found CM to induce
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epithelial-mesenchymal-transition and mammosphere for-
mation, as well as increased cell motility [23]. On the other
hand, interestingly, chemosensitivity of BCCs to anticancer
drugs was increased by ADSC-secreted factors, which might
yield to a potential adjunct for chemotherapeutic protocols.
Others found that exosome-mediated cell-to-cell contact
was a necessary step for ADSCs to increase tumor cell
proliferation [58, 117], with activation of the Wnt pathway as
a putative mechanism [46].
4.5. Obesity: Increased ADSC Pool. Obesity is a common
condition and has been associatedwith increased lifetime risk
of breast cancer development [118–121]. This has been linked
to increased levels of aromatases in WAT and raised levels
of estrogen. Surplus adipose tissue worsens the prognosis
at onset of breast cancer disease and can contribute to
drug resistance [72, 122]. Besides providing energy storage,
fat tissue is also regarded as an endocrine organ [123].
In fact, in postmenopausal women, fat remains the most
important estrogen production site [124]. WAT is also largely
present in the breast and exerts both paracrine and endocrine
actions on the mammary gland, as well as any developing
BCCs. Leptin, IL-6, TNF-𝛼, IFG, and other hormones are
upregulated in obese women and contribute to a state of
“chronic inflammation” [44, 125], which can promote breast
cancer growth [126]. Indeed, IL-6 has been shown to promote
invasion capability and is a marker for poor outcome in
breast cancer patients [39, 42, 127–129] and increased IL-6
serum levels are associated with increased metastatic spread
[130].
Obesity increases the overall availability and circulating
number of ADSCs [44]. Overweight mice have higher yields
of ADSCs in the blood stream [22]. ADSCs in obesemice dif-
ferentiatedmore frequently into tumor-associated adipocytes
and promoted tumor growth [39]. In a different setting, BCCs
inhibited adipogenesis of ADSCs, which, in turn, responded
with increasing proinflammatory signals, rearranging the
ECM [36]. However, it is still unclear whether these findings
have any relevance in the clinical setting.
Leptin found in obese patients promotesmacrophage dif-
ferentiation, increasing proinflammatory and proangiogenic
factor secretion. In a positive feedback loop, increased proin-
flammatory cytokines increase the amount of preadipocytes,
blocking their maturation to adipocytes, which again raises
the amount of inflammatory cytokines and leptin levels [131].
This sort of interplay is believed to be able to predispose
a patient to malignancy development [72]. The paracrine
mechanism for matrix metalloproteinase (MMP)-2, MMP-
9, and Twist1 expression is estrogen- and leptin-dependent
[72]. Leptin level also correlated with higher recurrence rates
in estrogen- and progesterone-receptor positive (ER+/PR+)
cancers, underscoring its role in increased invasiveness [72,
132]. In addition, as shown by Rhodes et al., BM-MSCs pro-
moted the growth of breast cancer estrogen-independently
[29]. The lack of hormone receptors on basal-like BCCs such
as MDA-MB-231 and SKBR-3 advocates for the hormone-
independent promoting effect of ADSCs in this type of breast
cancer. Interestingly, ADSCs from nonobese people had less
influence on BCC proliferation [72].
5. Effects of ADSCs on Migration and
Metastatic Spread
The spread of breast cancer to distant locations as well as
cancer recurrence worsens prognosis and patient survival
drastically and eventually accounts for most breast cancer-
related deaths [133]. To metastasize, cancer cells need to go
through a process, including invasion, migration through
stroma, extravasation, and engraftment in a remote, new
niche [134]. This happens directly into adjacent skin and
muscle or indirectly through the lymphatic system or blood
stream. Frequent distant metastasis sites are bone, brain,
lung, and liver [133]. Bone marrow in the skeleton has
been attributed to the promotion of growth of breast cancer
metastases, due to the presence of a heterogeneous marrow
stroma includingMSCs, EPCs, hematopoietic stem cells, and
fibroblasts among other types of cells, creating a particularly
suitable environment for proliferation. Thus, it is essential
to investigate and shed light on the effects that fat trans-
plantation to the breast and, more specifically, comprised
or implemented ADSCs might have in promoting breast
cancer invasion and progression. Several publications report
the potential enhancing effect of ADSCs on the metastatic
sequence of breast cancer [30, 39, 41, 42, 49, 71].
5.1. ADSCs Influence on Invasion andMigration. Amultitude
of ADSC-secreted factors are potentially able, alone or in
combination, to induce enhancedmigration and invasiveness
of breast cancer cells. IL-6, IL-8, MCP-1, RANTES, SDF-
1, TGF-𝛽1, and VEGF, among others, can shift BCCs to a
more aggressive cancer phenotype, resulting eventually in
increased metastatic occurrence [5, 93, 135].
SDF-1 is one important factor involved in the spread
of BCCs [31, 135]. Blocking CXCR-4 receptors significantly
revert the effect, even in the presence of BM-MSCs [31]. The
SDF-1 pathway especially is relevant to breast cancer metas-
tasizing to bone [136]. Importantly, CXCR-4 is also linked to
poor clinical outcome in patients with breast cancer [135].
In a similar fashion, ADSCs promoted BC spread through
a SDF-1-dependent mechanism both in vitro and in vivo
[30]. RANTES is another relevant factor secreted by ADSCs
involved in BCC migration [26, 30, 38]. Indeed, Karnoub
et al. described previously that BM-MSCs produce RANTES
when stimulated by BCCs, which in turn enhances their
motility and favors metastasizing [26]. A similar effect could
be expected for ADSCs as well. IL-6 and IL-8 are interleukins
linked to increased cancer invasion and migration [73, 137,
138]. Additionally, loss of ER has been found to correlate
with IL-8 upregulation and breast cancer progression in
ER− breast cancer cell lines [139]. Secretion of MMPs by
MSCs fosters breast cancer invasion and migration through
ECM modification. MMPs, a class of proteases, are involved
in restructuring the tumor stroma and are increasingly
expressed in the CME and believed to increase breast can-
cer invasion [133, 140–142]. MMP-9, for example, increases
metastasis without promoting cancer growth [141]. Similarly,
MMP-11 enables BCCs to migrate through complex bidi-
rectional signaling with local adipocytes and ADSCs [140].
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There is evidence that MMP-mediated BCC migration
depends on interplay between the different types of MMPs
and does not rely on a single MMP type [74].
5.2. Epithelial-to-Mesenchymal Transition. One important
mechanism by which MSCs have been shown to influence
cancer cells is turning premalignant or low malignant cells
into an invasive andmigratory phenotype through epithelial-
to-mesenchymal transition (EMT) [143, 144]. EMT, known
as a physiological process during development [145], has also
been implicated in lung [146], prostate [147, 148], and breast
cancer [23, 41, 60, 70]. During EMT, cells are unleashed
from their tight junctions, allowing them to escape into
the tumor/stroma complex and move through the ECM,
increasing their plasticity [149]. Cell propensity for migration
is increased, inducing a switch from in situ cancer to invasive
cancer types; invasion of blood vessels and production of
distant metastases are the consequences [150, 151]. MSCs can
induce morphological, functional, and molecular changes
in epithelial cancer cells, resulting in downregulation of
epithelial-specific markers and increased migration, poten-
tially promoting phenotype shifting and migration, generat-
ing migration-enabled CSCs, or both [70, 116, 149, 151].
Both BM-MSCs and ADSCs secrete many factors that
participate in inducing EMT in breast cancer [71, 131, 152–
154], and some ADSC subpopulations might be more prone
to inducing EMT than others [41]. Secreted TGF-𝛽1 and
IL-6 especially but also IL-8 and MMPs have been long
recognized to release cell-to-cell contacts of breast cancer
cells and initiate metastasizing behavior [130, 149, 151, 155–
157]. Additionally, hormones like leptin and osteopontin can
induce EMT [158, 159].
Upon induction, typical EMT genes are upregulated by
MSCs such as Slug, Snail1/2, Smad, and Twist1 [160–162].This
translates in a so-called cadherin-switch, which is a hallmark
of EMT, where E-cadherin is downregulated, N-cadherin is
upregulated [149, 152, 163], and mesenchymal proteins are
induced (e.g., Vimentin and Actin). CAFs are also able to
increase invasion and migration of luminal and basal type
BCCs through the TGF-𝛽1/Smad pathway [164]. Inhibition of
the TGF-𝛽1/Smad complex, indeed, has been found to reduce
BM-MSC-mediated breast cancer progression through a
repression of MSC-to-CAF differentiation [106].
Besides promoting invasion and metastasis, MSC-
induced EMT might confer self-renewal activity to BCCs.
Indeed, EMT might be at the basis of distant breast cancer
metastatic spread, generating CD44+ CSCs, which are
mesenchymal-like cells that can easily migrate into the blood
stream and extravasate and metastasize [70, 131, 165, 166].
Moreover, while other tumor cells aremore or less susceptible
to anticancer therapy, CSCs seem more resistant and
involved in progression to hormone-receptor negative and
chemotherapy-resistant tumor cells [165, 167–170].
6. Clinical Implications
The concept of grafting fat to the breast for aesthetic and
reconstructive purposes originated over a century ago but
has been again promoted over the last twenty years [4].
While initial concerns about detection of breast cancer
during screening have been refuted, the detection of ADSCs
as an active component of the autologous processed graft
has raised safety concerns. In general, evidence for ADSC
application for breast reconstruction after cancer surgery
is not voluminous. Nevertheless, several reports, mostly
clinical case series, show no evidence of increased cancer
occurrence after lipofilling, pointing out the importance of
appropriate oncological follow-up [171–173]. In one of the
biggest series of lipograft procedures after breast cancer, no
increased recurrence was found during a 10-year follow-
up [173], whereas higher recurrence rates were detected for
in situ breast carcinomas after breast conserving therapy
followed by autologous fat grafting in another group [174–
176]. It is important to note that these reports focus on
autologous fat transfer without added stem cells.
However, many reports differ with regard to patient num-
bers, patient selection criteria, follow-up length, and use of
controls [171–173, 177]. Some case reports suggest fat grafting-
related cancer recurrence, even though they fail to prove a
direct link [178–180].
The first clinical study that assessed stem cell-enriched
fat grafting in the postcancer scenario showed promising aes-
thetic results and no adverse events such as cancer recurrence
[181] during a very limited follow-up period of one year. The
study was criticized for only including low-risk patients and
for being designed without any controls [182].
Petit et al. published a large multicenter study with a
median follow-up of 19.2 months involving 513 breast cancer
patients. The authors did not find that autologous fat transfer
interfered with radio-oncological follow-up, but pointed out
the need for further studies with a strict and long-term
oncological follow-up period [174, 175]. The same authors
found increased local recurrence in a case-control study of
a specific subgroup of patients undergoing surgery for in situ
neoplasias with subsequent autologous lipofilling for breast
recontouring [174]. In 2013, they published an expanded
study with a larger cohort and a longer follow-up period and
confirmed the preliminary results, suggesting an increased
cancer risk in this particular patient collective. The results
might be due to an exceptionally low control incidence of
local events due to selection bias [176], but other authors
also agree that oncological safety could be better elucidated
[183–185]. These authors did not find an increased rate of
recurrence in the other patients studied, and other published
case series of breast fat grafting for reconstruction have not
shown an increased rate of local recurrence.
A small number of ongoing clinical trials are assess-
ing outcomes after stem cell-enhanced fat transfer to the
breast with a focus on aesthetic results (ClinicalTrial.gov;
NCT01756092 and NCT01801878) and oncological results. In
the GRATESC trial (NCT01035268), an ongoing prospective
randomized, multicenter study started in 2010; the authors
aim to investigate local and distant cancer recurrence after
lipofilling for breast shape and volume improvement after
breast conservative surgery, with a planned follow-up period
of five years.
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7. Discrepancies between Basic Science and
Its Clinical Translation
Overall, data regarding the influence of MSC and more in
particular ADSCs on breast cancer cells are controversial.
A few preclinical reports show decreased breast cancer cell
proliferation with high amounts of MSCs [23, 34, 94], even
in highly proliferative cell lines such as MDA-MB-231 [49,
95]. On the other hand, a variety of basic science reports
demonstrate a fostering effect of MSCs on breast cancer
growth, progression, andmetastasis [29, 36, 39, 41, 43, 60, 71].
The majority of these reports are raising concerns regarding
the use of ADSC for cell-assisted fat grafting for both
aesthetic and reconstructive procedures on the breast. These
experimental findings are not well substantiated by clinical
data thus far: there are a number of case series and one clinical
study pointing out at a higher local breast cancer recurrence
after lipofilling [175, 176, 178, 186]. Whether basic science is
solely unmasking a potential issue, which eventually is not
relevant enough to translate to clinical reality or if, indeed,
ADSC-enhanced lipofilling procedures bear oncological risk,
is an ongoing discussion.
This discrepancy can have several origins and definitely
needs to be addressed prior to routine use of this recon-
structive strategy. Many variables of the experimental setup
can influence the results. As an example, in the mentioned
studies, most of the utilized cells grow fast in vitro and
form large tumors in vivo, which might not reflect the actual
clinical reality. More likely, dormant, low active cells remain
unrecognized in the tumor bed after unsuccessful surgical
therapy than highly proliferative ones. Moreover, freshly
isolated primary breast cancer cells from tumor excisates
or MPEs [5] should be preferred for preclinical studies,
along with matched fat tissue and MSCs/ADSCs from the
same patient, as different donor biology can affect the MSC
functionality and thus the outcome [71]. Primary breast
cancer cells have been shown to have lower doubling times
[187] and may have different dormancy status which has to
be accounted for as well [5]. The timing of MSC addition
to the tumors is another important factor. For example,
injecting MSCs three weeks after BCC inoculation showed
decreased metastasizing in triple-negative breast cancer [95],
which is an important finding, as the chosen delayed timing
might more appropriately reflect the clinical scenario of
postcancer breast reconstruction. High amounts of tumor
cells as injected in many experimental studies in vivo might
not depict the clinical reality as well. Indeed, if residual cancer
cells remain in situ after breast cancer surgery, it is likely that
a low number of BCCs would be exposed to a significantly
higher number of ADSCs supplemented to fat grafts at the
time of reconstruction. Further, distinct MSC origins and
species, as well as different culture conditions [50], 2D culture
systems which fail to simulate the CME adequately, the
BCC-to-MSC ratio, and the route of administration for in
vivo studies are additional factors which might contribute to
controversial results.
On the clinical side, the actual data has to be carefully
analyzed. In our opinion, more clinical data is still needed
in strong evidence for safety with the use of cell-enhanced
fat transplantation. Generally, the available clinical study
data suggest safe application of unprocessed autologous fat
grafting. The study of Petit et al., with increased recurrent
local events after fat grafting in patients with in situ cancer of
the breast, so far is the only controlled study demonstrating
an increased risk of recurrence in a specific cancer subgroup
[176]. Larger controlled clinical trials are warranted and these
should avoid any selection bias due to sole inclusion of a
“favorable” patient population (i.e., mastectomies), which
is likely to provide lower recurrence rates than expected
after breast conserving surgery [183]. Additionally, large
scale registries, such as the American Society of Plastic
Surgeons fat grafting to the breast registry, should be broadly
implemented.
8. Conclusions
The majority of experimental studies trend to support the
propensity of MSCs and ADSCs in promoting growth, pro-
gression, and metastatic spread of residual or de novo breast
cancer after resection. In contrast, only a few clinical case
series and trials are reflective of similar findings.
Two scenarios are of interest. (1) Any residual unresected
microscopic tumor foci persisting after mastectomy could
be activated by ADSCs used in postsurgical restoration. (2)
Occult dormant cancer cells in patients with no diagnosed
breast cancer but undergoing ADSC therapies for breast
augmentation may undergo a malignant transformation.
Currently, the concerns of safety and the debate on
efficacy versus such unresolved risk remain ongoing until
larger randomized and controlled clinical trials shed light
on the scenario. Multiple recommendations based on exten-
sive reviews are available and may be useful for patient
information and selection. Overall, most of these studies do
not support using autologous stem cell-enhancement at the
present [185, 188–190], whereas whole fat grafting appears to
be safe in many circumstances.
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